Clarity in every comparison.What was approved?
Health Canada announced this semaglutide injection approval with Ozempic as the reference product. The announcement concerns type 2 diabetes; it is not an approval announcement for weight management.
A generic product should be checked against its specific reference, authorized uses, strength and presentation. A shared ingredient does not mean every semaglutide product can be substituted for every other one.
Product identity
1.34 mg/mL · presentations listed in recall. The August 27 recall identifies these DINs and affected lots for an impurity issue. Consult the current recall notice; approval does not establish current stock.
This is a selected product record, not a full catalogue of presentations. Match the DIN on your prescription or package to the current Health Canada entry.
Price and pharmacy availability
Recall: check with pharmacist. We have not verified a current cash quote for this exact product and package. Ask the pharmacy about stock, quantity, days supplied, dispensing charges and whether a recall affects the supplied lot.
Coverage and substitution
Ask the insurer about this DIN and the plan’s authorization requirements. Ask your pharmacist and prescriber whether any proposed substitution fits your prescription. Approval alone does not confirm provincial interchangeability, coverage or local stock.